跳至主要内容
临床试验/NCT03373201
NCT03373201已完成3 期

Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type Insomnia

Vanda Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 320 人开始时间: 2017年10月16日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
320
试验地点
1
主要终点
Total Sleep Time in the First Two Thirds of the Night

研究概览

简要总结

The aim of this study is to investigate tasimelteon vs. placebo on sleep in healthy individuals after a phase advance in jet lag type insomnia.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Ability and acceptance to provide written consent, fluent in English;
  • Healthy subjects with no medical, psychiatric or current sleep disorders;
  • Men or women between 18-75 years;
  • Body Mass Index of ≥ 18 and ≤ 30 kg/m2.

排除标准

  • Major surgery, trauma, illness or immobile for 3 or more days within the past month;
  • Pregnancy or recent pregnancy (within 6 weeks);
  • A positive test for drugs of abuse at the screening or evaluation visit.

研究组 & 干预措施

Tasimelteon

Experimental

干预措施: Tasimelteon (Drug)

Placebo

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

Total Sleep Time in the First Two Thirds of the Night

时间窗: 1 Day

Total sleep time during the first 2/3 of the night following an 8-hour phase advance bedtime, as measured by PSG. This is representative of trans meridian travel across 8 time zones.

次要结局

  • Next Day Alertness as Measured by the Karolinska Sleepiness Scale (Night 1 Average Score)(1 Day)
  • Total Sleep Time(1 Day)
  • Latency to Persistent Sleep(1 Day)
  • Wake After Sleep Onset(1 Day)
  • Next Day Alertness as Measured by the Visual Analogue Scale (Night 1 Average Score)(1 Day)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验